His primary areas of investigation include Epstein–Barr virus, Virology, Virus, Antigen and Molecular biology. His Epstein–Barr virus research is multidisciplinary, incorporating perspectives in B cell, Gene, Lymphoma, Lytic cycle and Gammaherpesvirinae. His Virology study combines topics from a wide range of disciplines, such as Gene expression and Pathogenesis.
His Virus research focuses on Virus latency in particular. His Antigen research focuses on Epstein–Barr virus infection and how it relates to Cell biology. The study incorporates disciplines such as Promoter, Transcription, Binding site and Effector in addition to Molecular biology.
Andrew I. Bell mostly deals with Epstein–Barr virus, Virology, Virus, Molecular biology and Immunology. He has included themes like Virus latency, Cancer research, B cell, Lytic cycle and Gammaherpesvirinae in his Epstein–Barr virus study. His research in Virology intersects with topics in Gene expression, T cell, Germinal center, Antigen and Immunoglobulin D.
His research integrates issues of Burkitt's lymphoma, Lymphoma, Apoptosis and Pathogenesis in his study of Virus. Andrew I. Bell has researched Molecular biology in several fields, including Transcription, Transcription factor, Gene, Promoter and Binding site. His biological study spans a wide range of topics, including RNA polymerase and Escherichia coli.
Epstein–Barr virus, Virology, Virus, Immunology and Epstein–Barr virus infection are his primary areas of study. His work carried out in the field of Epstein–Barr virus brings together such families of science as Messenger RNA, Gene, Cell growth and Lytic cycle. Andrew I. Bell studies Virus latency which is a part of Virology.
His study in Virus is interdisciplinary in nature, drawing from both Pathogenesis, Cellular Oncogenes, Oncogene, Molecular biology and Lymphoma. The concepts of his Molecular biology study are interwoven with issues in Promoter, Response element, Transcription factor and Transcription. Andrew I. Bell focuses mostly in the field of Epstein–Barr virus infection, narrowing it down to matters related to Antibody and, in some cases, Human leukocyte antigen.
His primary areas of study are Virus, Epstein–Barr virus, Virology, Lymphoma and Pathogenesis. His Virus research incorporates themes from Molecular biology, Messenger RNA, Gene and Lymphocytosis. Andrew I. Bell is involved in the study of Epstein–Barr virus that focuses on Epstein–Barr virus infection in particular.
His Virology study frequently draws connections between adjacent fields such as Immunology. His Lymphoma research is multidisciplinary, incorporating elements of Oncovirus, Viral entry, Lymphatic system, Lytic cycle and Transcription. His studies in Pathogenesis integrate themes in fields like Chromosomal translocation, Cellular Oncogenes, Oncogene, Diffuse large B-cell lymphoma and Biopsy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Stringent spacing requirements for transcription activation by CRP.
Kevin Gaston;Andrew Bell;Annie Kolb;Henri Buc.
Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2
Gemma Kelly;Andrew Bell;Alan Rickinson.
Nature Medicine (2002)
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription
Andrew Bell;Kevin Gaston;Roy Williams;Karen Chapman.
Nucleic Acids Research (1990)
Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.
Carol Nonkwelo;Julia Skinner;Andrew Bell;Alan Rickinson.
Journal of Virology (1996)
An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link
Gemma L. Kelly;Heather M. Long;Julianna Stylianou;Wendy A. Thomas.
PLOS Pathogens (2009)
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma
Judith M. Timms;Andrew Bell;Joanne R. Flavell;Paul G. Murray.
The Lancet (2003)
Epstein–Barr virus-associated lymphomas
Claire Shannon-Lowe;Alan B. Rickinson;Andrew I. Bell.
Philosophical Transactions of the Royal Society B (2017)
Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells
Gemma L. Kelly;Anne E. Milner;Gouri S. Baldwin;Andrew I. Bell.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain.
Fiona Nitsche;Andrew Bell;Alan Rickinson.
Journal of Virology (1997)
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
Andrew I. Bell;Katherine Groves;Gemma L. Kelly;Debbie Croom-Carter.
Journal of General Virology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: